Cathepsin E drives colorectal cancer progression and immune evasion via ZNF326 ADP-ribosylation and TGF-β/SMAD activation
CTSE drives CRC progression by stabilizing ZNF326 via ADP-ribosylation and activating TGF-β/SMAD pathway, while facilitating tumor immune evasion. CTSE represents a promising therapeutic target for CRC, and its combination with PD-1/PD-L1 inhibitors may synergistically enhance anti-tumor efficacy.
Authors
- Jie Feng (ORCID: https://orcid.org/0000-0002-6265-0215)
- Mengxin Zhu
- Qinhua Xi (ORCID: https://orcid.org/0000-0002-0629-7867)
- Tongguo Shi (ORCID: https://orcid.org/0000-0002-5382-2775)
- Huan Zhang
Institutions
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2026-03-14
- DOI
- https://doi.org/10.1186/s12967-026-07995-5
- Primary Topic
- Protease and Inhibitor Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00